Stockholm - Free Realtime Quote SEK

Oncopeptides AB (publ) (ONCO.ST)

Compare

2.0650

-0.0200

(-0.96%)

As of 11:19 AM GMT+2. Market Open.

Currency in SEK All numbers in thousands

Download

Breakdown

TTM

12/31/2023

12/31/2022

12/31/2021

12/31/2020

Total Revenue

21,369.0000

35,220.0000

8,355.0000

118,295.0000

Cost of Revenue

119.0000

-1,079.0000

6.0000

53,121.0000

Gross Profit

21,250.0000

36,299.0000

8,349.0000

65,174.0000

Operating Expense

279,536.0000

290,843.0000

360,485.0000

1,486,091.0000

1,591,279.0000

Operating Income

-258,286.0000

-254,544.0000

-352,136.0000

-1,420,917.0000

-1,591,279.0000

Net Non Operating Interest Income Expense

-5,536.0000

2,807.0000

1,733.0000

-456.0000

-1,163.0000

Pretax Income

-260,532.0000

-248,447.0000

-337,680.0000

-1,421,372.0000

-1,592,442.0000

Tax Provision

2,170.0000

664.0000

271.0000

8,946.0000

2,251.0000

Net Income Common Stockholders

-262,702.0000

-249,111.0000

-337,951.0000

-1,430,317.0000

-1,594,693.0000

Diluted NI Available to Com Stockholders

-262,702.0000

-249,111.0000

-337,951.0000

-1,430,317.0000

-1,594,693.0000

Basic EPS

-1.72

-1.97

-2.93

-13.54

-18.22

Diluted EPS

-1.72

-1.97

-2.93

-13.54

-18.22

Basic Average Shares

211,263.9030

126,835.6180

115,513.0390

105,651.2110

87,517.4040

Diluted Average Shares

211,263.9030

126,835.6180

115,513.0390

105,651.2110

87,517.4040

Total Operating Income as Reported

-257,189.0000

-253,447.0000

-349,350.0000

-1,420,917.0000

-1,591,279.0000

Total Expenses

279,655.0000

289,764.0000

360,491.0000

1,539,212.0000

1,591,279.0000

Net Income from Continuing & Discontinued Operation

-262,702.0000

-249,111.0000

-337,951.0000

-1,430,317.0000

-1,594,693.0000

Normalized Income

-262,702.0000

-249,111.0000

-337,951.0000

-1,430,317.0000

-1,594,693.0000

Interest Income

8,592.0000

2,616.0000

492.0000

322.0000

Interest Expense

528.0000

5,785.0000

883.0000

948.0000

1,485.0000

Net Interest Income

-5,536.0000

2,807.0000

1,733.0000

-456.0000

-1,163.0000

EBIT

-246,404.0000

-242,662.0000

-336,797.0000

-1,420,424.0000

-1,590,957.0000

EBITDA

-246,404.0000

-231,622.0000

-319,636.0000

-1,405,430.0000

-1,576,554.0000

Reconciled Cost of Revenue

119.0000

-1,079.0000

6.0000

53,121.0000

Reconciled Depreciation

4,540.0000

11,040.0000

17,161.0000

14,994.0000

14,403.0000

Net Income from Continuing Operation Net Minority Interest

-262,702.0000

-249,111.0000

-337,951.0000

-1,430,317.0000

-1,594,693.0000

Normalized EBITDA

-246,404.0000

-231,622.0000

-319,636.0000

-1,405,430.0000

-1,576,554.0000

Tax Rate for Calcs

0.0002

12/31/2020 - 2/22/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

ATORX.ST Alligator Bioscience AB (publ)

1.1980

-5.07%

KAN.ST Kancera AB (publ)

1.8880

0.00%

ACE.ST Ascelia Pharma AB (publ)

2.2150

+0.45%

QUIA.ST Quia Pharma AB (publ)

0.0191

-4.50%

XBRANE.ST Xbrane Biopharma AB (publ)

0.2170

+20.56%

LPGO.ST Lipigon Pharmaceuticals AB (publ)

0.1854

+0.76%

CYXO.ST Cyxone AB (publ)

0.0410

+2.50%

ABLI.ST Abliva AB (publ)

0.1572

+1.42%

ULTI.OL Ultimovacs ASA

1.8600

+2.20%

EGTX.ST Egetis Therapeutics AB (publ)

4.7100

+0.11%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Oncopeptides AB (publ) (ONCO.ST)

Upgrade to begin using 40 years of financial statements and get so much more.

Related Tickers